During the second week of February, the ProVac team initiated and concluded a cost-effectiveness analysis (CEA) of the pneumococcal conjugate vaccines (PCV) in Peru and El Salvador, respectively.
On February 7, the ProVac Initiative convened a group of national professionals from several disciplines to define relevant policy questions and discuss available data sources with respect to the introduction of a PCV. Striving to make evidence-based decisions on new vaccine introduction, Peru plans to evaluate the costs and benefits of introducing PCV-10 or PCV-13 as well as potential long-term impact of PCVs on nutrition indicators. Professionals from Peru’s Expanded Program on Immunization (EPI), a research team from the National Health Institute, and professionals from other relevant government offices were trained on ProVac’s TRIVAC model, a comprehensive cost-effectiveness model for childhood vaccines, including those that protect against Hib, pneumococcal and rotavirus disease. After reviewing the model, the national team proposed potential data sources for each model parameter and drafted a study timeline. The CEA is expected to be finalized in March.
On February 9-10, the ProVac Initiative held working sessions in San Salvador to conclude a CEA on PCVs in El Salvador. The ProVac team provided technical reviews of model parameters and led discussions on final results. After defining alternative scenarios to analyze, the national team finalized materials to present to the Minister of Health. The study concluded that both the 10 and 13-valent vaccines are cost-effective interventions to prevent pneumococcal disease in children under 5 years of age in El Salvador. These results are discussed in depth in El Salvador’s final report and will be published soon.
Published in Global Immunization Newsletter, February 2012.